Analysts predict that BRAINSWAY LTD/S (NASDAQ:BWAY) will announce $5.30 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for BRAINSWAY LTD/S’s earnings. The firm is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that BRAINSWAY LTD/S will report full year sales of $22.35 million for the current fiscal year, with estimates ranging from $22.30 million to $22.40 million. For the next financial year, analysts expect that the firm will report sales of $30.00 million, with estimates ranging from $29.50 million to $30.50 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover BRAINSWAY LTD/S.

BRAINSWAY LTD/S (NASDAQ:BWAY) last released its earnings results on Wednesday, May 29th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.02. The company had revenue of $5.18 million during the quarter, compared to analysts’ expectations of $5.00 million.

A number of research analysts have recently weighed in on the stock. LADENBURG THALM/SH SH downgraded shares of PennantPark Investment from a “buy” rating to a “neutral” rating in a report on Monday, May 13th. Raymond James restated a “neutral” rating and set a $35.00 price target on shares of Stantec in a report on Monday, May 13th. CIBC raised their price target on shares of NorthWest Health Prop Real Est Inv Trust from C$11.75 to C$12.00 in a report on Monday, May 13th. Cantor Fitzgerald assumed coverage on shares of CytomX Therapeutics in a report on Monday, May 13th. They set an “overweight” rating and a $21.00 price target on the stock. Finally, Oppenheimer raised their price target on shares of Novavax from $1.25 to $25.00 in a report on Monday, May 13th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $15.80.

BWAY stock traded down $0.10 during midday trading on Thursday, reaching $10.00. The company had a trading volume of 3,200 shares, compared to its average volume of 14,387. BRAINSWAY LTD/S has a 1 year low of $8.00 and a 1 year high of $12.39. The company has a quick ratio of 1.33, a current ratio of 1.33 and a debt-to-equity ratio of 0.32. The company’s 50 day moving average price is $9.93.

BRAINSWAY LTD/S Company Profile

Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.

Featured Story: Why is the price-sales ratio important?

Get a free copy of the Zacks research report on BRAINSWAY LTD/S (BWAY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with's FREE daily email newsletter.